Table of Contents:
Chapter 1. Research Methodology and Scope
- Market Segmentation and Scope
- Regional Coverage
- Objectives
- Research Methodology
Chapter 2. Executive Summary
- Market Landscape
- Market Size & Forecast
- Competitive Landscape
Chapter 3. Complement Inhibitors (C3/C5) Market: By Product Type Trends, Size, and Future Outlook
- By Product Type Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Product Type Definitions, Technology Landscape
- By Product Type Market Drivers
- Product Launches
- Technology Launches
- Other Market Drivers
- By Product Type Market Restraints
Chapter 4. Complement Inhibitors (C3/C5) Market: By Route of Administration Trends, Size, and Future Outlook
- By Route of Administration Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Route of Administration Definitions, Technology Landscape
- By Route of Administration Market Drivers
- Product Launches
- Technology Launches
- Other Market Drivers
- By Route of Administration Market Restraints
Chapter 5. Complement Inhibitors (C3/C5) Market: By Indication Trends, Size, and Future Outlook
- By Indication Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Indication Definitions, Technology Landscape
- By Indication Market Drivers
- Product Launches
- Technology Launches
- Other Market Drivers
- By Indication Market Restraints
Chapter 6. Complement Inhibitors (C3/C5) Market: By Mechanism of Action Trends, Size, and Future Outlook
- By Mechanism of Action Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Mechanism of Action Definitions, Technology Landscape
- By Mechanism of Action Market Drivers
- Product Launches
- Technology Launches
- Other Market Drivers
- By Mechanism of Action Market Restraints
Chapter 7. Complement Inhibitors (C3/C5) Market: By Distribution Channel Trends, Size, and Future Outlook
- By Distribution Channel Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Distribution Channel Definitions, Technology Landscape
- By Distribution Channel Market Drivers
- Product Launches
- Technology Launches
- Other Market Drivers
- By Distribution Channel Market Restraints
Chapter 8. Complement Inhibitors (C3/C5) Market: By End-User Trends, Size, and Future Outlook
- By End-User Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By End-User Definitions, Technology Landscape
- By End-User Market Drivers
- Product Launches
- Technology Launches
- Other Market Drivers
- By End-User Market Restraints
Chapter 9. Complement Inhibitors (C3/C5) Market: Regional Market Trends, Size, and Future Outlook
- North America
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Other Market Drivers
- Market Restraints
- Competitive Outlook
- Europe
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Other Market Drivers
- Market Restraints
- Competitive Outlook
- Asia Pacific
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Other Market Drivers
- Market Restraints
- Competitive Outlook
- Latin America
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Other Market Drivers
- Market Restraints
- Competitive Outlook
- Middle East, and Africa
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Other Market Drivers
- Market Restraints
- Competitive Outlook
Chapter 10. Complement Inhibitors (C3/C5) Market: Competitive Landscape
- Alexion Pharmaceuticals (AstraZeneca)
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Apellis Pharmaceuticals
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Novartis AG
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Chugai Pharmaceutical Co., Ltd.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Omeros Corporation
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Regeneron Pharmaceuticals
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Shire (Takeda Pharmaceutical Company Limited)
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Genentech (Roche)
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Amyndas Pharmaceuticals
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Akari Therapeutics
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Achillion Pharmaceutical
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Bio-Thera Solutions
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Biocryst Pharmaceuticals
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Gemini Therapeutics
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Catalyst Biosciences
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Morphic Therapeutic
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Pieris Pharmaceuticals
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Viela Bio (Horizon Therapeutics)
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Alnylam Pharmaceuticals
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Visterra (Subsidiary of Otsuka Pharmaceutical Co., Ltd.)
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
Research Methodology
- Primary Research
- Secondary Research
- Assumptions
- IDataAcumen Analysis
- Paid Databases
Appendix
- About Us
Frequently Asked Questions
The current market size of the Complement Inhibitors (C3/C5) industry is approximately USD 3.2 billion.
Increasing prevalence of complement-mediated diseases, unmet medical needs, rising awareness, early diagnosis, favorable regulatory environment, development of novel therapies, expanding indications, strategic collaborations, and increasing healthcare expenditure.
High costs of complement inhibitors, patent expiries and biosimilar competition, stringent regulatory requirements, limited treatment accessibility in developing regions, and lack of awareness in certain regions.
The leading component segment in the Complement Inhibitors (C3/C5) Market is the C5 Inhibitors segment, used for treating conditions like PNH and aHUS.
Alexion Pharmaceuticals (AstraZeneca), Apellis Pharmaceuticals, Novartis AG, Chugai Pharmaceutical Co., Ltd., Omeros Corporation, Regeneron Pharmaceuticals, Shire (Takeda Pharmaceutical Company Limited), Genentech (Roche), Amyndas Pharmaceuticals, and Akari Therapeutics.
The North America region is expected to lead the Complement Inhibitors (C3/C5) Market, with a projected market size of USD 9.9 billion by 2031 and a CAGR of 15.2% during the forecast period of 2024-2031.
Increasing prevalence of complement-mediated diseases, unmet medical needs, rising awareness, early diagnosis, favorable regulatory environment, development of novel therapies, expanding indications, and increasing healthcare expenditure.